Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05807126 |
| Title | Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | National Cancer Institute (NCI) |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| UC Irvine Health Cancer Center-Newport | Costa Mesa | California | 92627 | United States | Details | |
| UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California | 92868 | United States | Details | |
| Montefiore Medical Center-Einstein Campus | Bronx | New York | 10461 | United States | Details | |
| Montefiore Medical Center - Moses Campus | Bronx | New York | 10467 | United States | Details | |
| University of Pittsburgh Cancer Institute (UPCI) | Pittsburgh | Pennsylvania | 15232 | United States | Details |